Compare AMZE & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMZE | ACXP |
|---|---|---|
| Founded | 2019 | 2017 |
| Country | United States | United States |
| Employees | 28 | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9M | 6.6M |
| IPO Year | N/A | 2021 |
| Metric | AMZE | ACXP |
|---|---|---|
| Price | $0.13 | $1.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.00 | ★ $95.50 |
| AVG Volume (30 Days) | ★ 6.9M | 66.5K |
| Earning Date | 05-19-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,986.62 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.11 | $0.29 |
| 52 Week High | $11.70 | $8.34 |
| Indicator | AMZE | ACXP |
|---|---|---|
| Relative Strength Index (RSI) | 44.95 | 37.37 |
| Support Level | $0.12 | $1.37 |
| Resistance Level | $0.20 | $1.75 |
| Average True Range (ATR) | 0.01 | 0.11 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 24.60 | 28.80 |
Amaze Holdings Inc is a technology-enabled, creator-powered commerce platform that enables creators, brands, and consumers to transact at scale. The Company provides infrastructure for creators and brands to design, launch, market, and fulfill products. The Company operates in two segments: E-commerce / Subscriptions, which includes the Amaze platform and creator commerce operations supporting product sales, subscription offerings, and digital content delivery; and Wine Products, which includes the sale of Fresh Vine wines through wholesale and direct-to-consumer channels across the United States and Puerto Rico.
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.